The research team, led by Joon Young Song of Korea University College of Medicine together with colleagues from Seoul National University, IQVIA and Merck, set out to quantify a gap that has long frustrated epidemiologists in the region. Reliable information on how pneumococcal disease affects adults in South Korea, and on whether vaccination programs have altered that picture, has been limited. To fill it, the investigators turned to one of the most powerful tools available in modern health research: a nationwide claims database covering virtually the entire population. They identified every hospitalization episode among adults aged 18 and older coded as invasive pneumococcal disease or pneumonia between 1 January 2010 and 31 December 2019, using the Korean version of the International Classification of Diseases to flag cases.

The study window was deliberately split around the 2014 vaccine rollout. Hospitalizations from 2010 to 2013 served as the pre-vaccination baseline, while those from 2015 to 2019 captured the post-introduction era, with the transition year excluded to allow the program to take hold. Rather than simply comparing average rates between the two periods, the researchers applied interrupted time series analysis, a statistical technique that separates an abrupt change in the level of a trend from a gradual change in its slope. Results were expressed as incidence rate ratios, with a value above 1 signaling an increase and a confidence interval crossing 1 indicating statistical uncertainty.

Over the full ten years, the database yielded 1,682 hospitalization episodes of invasive pneumococcal disease and 8,635 episodes of pneumonia among adults. Those raw counts translate into overall incidence rates of 0.4 episodes per 100,000 person-years for invasive disease and 2.1 per 100,000 person-years for pneumonia. Behind those averages lay a stark mortality gradient: 14.9 percent of adults hospitalized with invasive pneumococcal disease died, compared with 3.0 percent of those admitted with pneumonia. The burden was consistently concentrated among people aged 65 and older, the group in which pneumococcal infection most often turns fatal.

The interrupted time series results told two very different stories. For invasive pneumococcal disease, neither the level nor the slope of incidence changed significantly after the childhood program began. The level ratio was 1.26 with a 95 percent confidence interval of 0.99 to 1.59, just shy of conventional significance, and the slope ratio of 0.97, with an interval of 0.93 to 1.01, offered no evidence of a declining trend. In plain terms, the feared invasive infections, which include bacteremia and meningitis, neither dropped as herd-effect optimists might have hoped nor surged in any statistically convincing way. The adult burden simply persisted.

Pneumonia told a more surprising tale. The level of pneumonia incidence in the post-vaccination period was significantly higher than before, with an incidence rate ratio of 1.92 and a confidence interval of 1.51 to 2.42, meaning the post-program level was nearly double the baseline. The slope, however, was statistically flat, at 1.02 with an interval of 1.00 to 1.04, indicating that rates were not climbing year over year but had shifted upward as a step. The economic dimension followed the same pattern: the average total direct cost per pneumonia episode rose from 3.1 million Korean Won before the program to 4.1 million Won after it, an increase that ripples through a national health system when multiplied across thousands of admissions.

Why would a vaccine that protects children appear to coincide with more adult pneumonia? The authors are careful to avoid overinterpreting the association, and they point to several plausible explanations. Increased surveillance and heightened diagnostic awareness, particularly around respiratory illness, may have driven more hospitalizations to be coded and counted as pneumonia in the later period, inflating apparent incidence without a true rise in disease. Changes in coding practice, an aging population and shifting healthcare-seeking behavior could all contribute. It is also worth noting that pneumonia is a clinically broad category: many pneumonias in adults are not caused by pneumococcus at all, so a vaccine targeting one bacterium would not be expected to reverse trends driven by viruses and other pathogens.

The stability of invasive pneumococcal disease is equally instructive. Indirect, or herd, protection from childhood conjugate vaccination has been documented in several high-income countries, where declines in vaccine-type invasive disease among adults followed pediatric immunization. But the magnitude of that effect depends on how much of adult carriage and disease is caused by the strains covered by the vaccine, on how quickly non-vaccine strains fill the vacated ecological niche, and on adult vaccination coverage with the older polysaccharide vaccine, PPSV23, which South Korea has also deployed in older adults. The new study cannot disentangle these forces, but its results suggest that in the South Korean setting, the indirect benefit to adults from PCV13 in children was not strong enough to bend the invasive disease curve within five years.

The study comes with strengths and caveats that readers should weigh. Its great advantage is scale: a population-based database spanning a full decade, capturing hospitalizations across the entire country rather than a sample of sentinel hospitals. Its limitations are those inherent to claims data. Case identification relied on diagnostic codes rather than bacterial culture or polymerase chain reaction confirmation, so some episodes coded as pneumonia may not have been pneumococcal, and some true pneumococcal pneumonias may have been missed. The study was funded by Merck Sharp & Dohme, a subsidiary of Merck & Co., with study activities contracted to IQVIA, and several authors are employees or paid consultants of those companies, relationships disclosed in the publication. The descriptive design also means the analysis shows temporal association, not causation.

For policymakers, the message is less a verdict on PCV13 than a reminder that childhood immunization is not a complete answer for adult respiratory disease. The authors conclude that the incidence of invasive pneumococcal disease in South Korean adults remained stable while the incidence and economic burden of pneumonia increased after the vaccine entered the childhood program, and that vaccine use alongside factors such as increased surveillance may explain the observed results. As newer, higher-valency conjugate vaccines reach adult immunization schedules worldwide, studies like this one underscore the need for direct adult vaccination strategies, robust surveillance that can distinguish pneumococcal from non-pneumococcal pneumonia, and continued economic evaluation of who bears the cost when prevention falls short. The decade of Korean data suggests that protecting the oldest adults may require protecting them directly.

Subject of Research: Impact of childhood PCV13 vaccination on hospitalized adult pneumococcal disease in South Korea

Article Title: Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in South Korea – a population-based retrospective database study

Article References: Song, J. Y., Choi, E. H., Choe, Y. J., Yeo, S.-H., Patel, D., Lim, C. T. K., Lee, Y. E., Yamada, E., & Sukarom, I. (2026). Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in South Korea – a population-based retrospective database study. BMC Public Health. https://doi.org/10.1186/s12889-026-29058-6

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29058-6

Keywords: pneumococcal disease, PCV13, pneumonia, vaccination, herd immunity, South Korea, epidemiology, invasive pneumococcal disease, healthcare costs, public health, National Health Information Database, interrupted time series

The trial was designed as a prospective, open-label, multicenter, active-controlled study conducted across 31 clinical sites in India, enrolling healthy infants who had never received a pneumococcal conjugate vaccine. Participants aged 6 to 8 weeks at enrollment received three primary doses of either BE-PCV14 or Prevenar 13, followed by a booster dose administered at 12 to 15 months of age, a regimen commonly described as a 3p plus 1 schedule. The investigators, led by Subhash Thuluva of Biological E Limited in Hyderabad, measured serotype-specific immunoglobulin G antibodies against all 14 vaccine serotypes as well as the cross-protective serotype 6A, assessed 28 days after the booster dose. The primary immunological benchmarks were seroresponse rates, defined as the proportion of children achieving serotype-specific IgG concentrations of at least 0.35 micrograms per milliliter, a threshold long used as a correlate of protection against invasive pneumococcal disease, along with geometric mean concentrations of antibody.

The immunogenicity analysis included 559 children who received BE-PCV14 and 147 who received PCV13, providing a substantial evidence base for the comparison. The results were striking in their consistency: after the booster dose, seroresponse rates with BE-PCV14 reached at least 92.8 percent for every one of the 14 vaccine serotypes, and climbed to 96.2 percent for serotype 6A, which is not itself in the vaccine but is known to elicit cross-protection through immunological relatedness to vaccine serotype 6B. For the serotypes shared between the two vaccines, the immune responses elicited by BE-PCV14 were comparable to those generated by Prevenar 13, and post hoc statistical analyses formally demonstrated non-inferiority for all 14 serotypes by both seroresponse and antibody concentration criteria.

The non-inferiority assessment deserves particular attention because of its methodological rigor. The investigators pre-specified that BE-PCV14 would be considered non-inferior to PCV13 for a given serotype if the lower bound of the 95 percent confidence interval for the difference in seroresponse rates exceeded minus 10 percent, and if the lower bound of the confidence interval for the ratio of geometric mean concentrations exceeded 0.5. These are the kinds of thresholds that regulators and vaccine advisory bodies use to judge whether a new product can reasonably substitute for an established one. BE-PCV14 cleared both hurdles for all 14 serotypes, a result that, in the words of the trial team, establishes the vaccine as a credible alternative within existing infant immunization schedules rather than an entirely new paradigm requiring altered dosing strategies.

Perhaps the most consequential finding involves serotypes 22F and 33F, the two additional strains incorporated into BE-PCV14 that are absent from PCV13. The vaccine induced strong antibody responses to both, with booster-induced increases in antibody concentration ranging from 2.4-fold to 5.3-fold across serotypes when compared with pre-booster levels. This matters because pneumococcal serotype replacement is a well-documented phenomenon: when a vaccine eliminates the strains it targets, other strains that were previously less common can expand to fill the ecological vacuum. Serotypes 22F and 33F have been increasingly recognized as causes of invasive pneumococcal disease in countries that have deployed PCV13 at scale, and their inclusion in a new vaccine represents a forward-looking strategy intended to stay ahead of shifting disease epidemiology rather than merely replicate existing coverage.

Safety data from the trial were equally reassuring. Adverse events occurred at similarly low frequencies in both vaccine groups and were predominantly mild local reactions, such as injection-site tenderness or redness, or transient fever. Only two serious adverse events were recorded among BE-PCV14 recipients, and the investigators judged neither to be related to vaccination. The safety profile through 28 days after the booster dose, therefore, mirrors the well-characterized tolerability of licensed pneumococcal conjugate vaccines, an essential consideration for a product intended for universal infant immunization in resource-constrained settings where health systems may have limited capacity to manage vaccine-associated complications.

The trial, registered prospectively with the Clinical Trials Registry of India under identifier CTRI/2023/09/057894 and approved by India’s Central Drugs Standard Control Organisation, was conducted according to the Declaration of Helsinki and Good Clinical Practice guidelines, with written informed consent obtained from the parents or legally authorized representatives of all participants. Ethics committees overseeing each of the 31 participating sites granted approval, including the Institutional Ethics Committee of the All India Institute of Medical Sciences. The study, funded entirely by Biological E Limited, carries the inherent limitation that many of the authors are or were employees of the sponsoring company, though the trial’s active-controlled design against a licensed comparator and its prespecified statistical criteria provide meaningful safeguards against bias in the immunogenicity conclusions.

The public health significance of this work extends well beyond India’s borders. Streptococcus pneumoniae is responsible for hundreds of thousands of deaths among children under five each year, with the overwhelming majority occurring in low- and middle-income countries where access to effective vaccines has historically lagged behind wealthy nations. Pneumococcal conjugate vaccines have traditionally been among the most expensive components of childhood immunization schedules, and the introduction of a WHO-prequalified vaccine manufactured in a middle-income country carries the potential to lower prices, expand supply, and reduce dependence on a small number of multinational manufacturers. For India, which runs one of the largest immunization programs in the world through its Universal Immunization Programme, a domestically produced 14-valent vaccine that slots into the standard 3-plus-1 schedule offers both strategic and epidemiological advantages.

The trial’s findings also speak to a broader evolution in pneumococcal vaccine science. The 0.35 micrograms per milliliter IgG threshold used in this study is a population-level benchmark derived from efficacy trials of earlier conjugate vaccines, and while it does not guarantee individual protection, it remains the standard immunological bridge for licensure and comparison of new formulations. The demonstrated booster response, with antibody concentrations rising severalfold after the toddler dose, indicates that BE-PCV14 successfully exploits the immunological memory established during the primary series, an attribute that underpins the durability of protection in the second year of life, when the burden of invasive pneumococcal disease and pneumonia peaks in unvaccinated populations.

As pneumococcal disease patterns continue to shift under the selective pressure of global vaccination, the arrival of a well-tolerated, immunogenic 14-valent conjugate vaccine that extends coverage to emerging serotypes while matching the performance of the established 13-valent standard represents a meaningful advance. The authors conclude that PNEUBEVAX 14, when used as a booster in a 3-plus-1 schedule, is well tolerated and elicits robust responses comparable to PCV13 for shared serotypes while effectively broadening coverage to 15 serotypes when cross-protection against 6A is counted. For immunization programs weighing how to future-proof their pneumococcal strategies, this trial provides a substantial and encouraging body of evidence that broader serotype coverage need not come at the cost of safety or immunogenicity.

Subject of Research: Safety and immunogenicity of a 14-valent pneumococcal conjugate vaccine in Indian infants and toddlers

Article Title: Safety and immunogenicity of a 14-valent pneumococcal conjugate vaccine (BE-PCV14) administered in a 3p + 1 schedule to healthy Indian infants and toddlers: a prospective, multicenter, active-controlled phase IV trial

Article References: Thuluva, S., Gunneri, S., Ningaiah, S., Yerroju, V., Mogulla, R. R., Dhar, C., Thammireddy, K., Desai, S., Paliwal, P., Loka, C., Esanakarra, R., Narayandas, S., Chakravarthy, B. S., Narayan, J. P., Mahantshetti, N. S., Narang, M., Karayar, R. A., Verma, S., Thakkar, P. A., & Prabhakar, J. P. (2026). Safety and immunogenicity of a 14-valent pneumococcal conjugate vaccine (BE-PCV14) administered in a 3p + 1 schedule to healthy Indian infants and toddlers: a prospective, multicenter, active-controlled phase IV trial. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14412-1

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14412-1

Keywords: pneumococcal conjugate vaccine, PNEUBEVAX 14, BE-PCV14, PCV13, infant immunization, serotype 22F, serotype 33F, invasive pneumococcal disease, India, phase IV trial, booster vaccination, Streptococcus pneumoniae